ClinicalTrials.gg
CompletedNCT03449381Updated Mar 31, 2026

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

A Phase 1 interventional study of BI 907828 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 27 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
266
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is open to adults with different types of advanced cancer (solid tumors). The purpose of this study is to find out the most suitable dose of BI 907828 (brigimadlin) the participants can tolerate. The most suitable dose is used in the second part to find out whether brigimadlin makes tumors shrink.

In this study, brigimadlin is given to humans for the first time. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Brigimadlin is taken as a tablet. Participants either take a dose of brigimadlin on one day every 3 weeks or on two days every 4 weeks.

The participants are in the study for as long as they benefit from and can tolerate treatment. The doctors regularly check the participants' general health during the study.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 266 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written form ICF in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses.
  • documented, advanced solid tumors.
  • Patients fulfilling one or more of the following criteria:

    • Radiologically documented disease progression or relapse
    • Patients who are not eligible to receive standard of care treatments, and for whom no proven treatments exist.
    • Patients with MDM2 amplified sarcomas who require treatment (for Ph Ib/dose expansion - Cohort 1 only).
  • Patients with MDM2 amplified sarcomas may fulfil any one of the above three criteria to be considered eligible.
  • Phase Ia (dose escalation) only:
  • Patient has a tumor with either a known TP53 wild type status, or unknown TP53 status, and regardless of MDM2 amplification status, at the time of study entry.
  • Phase Ib (expansion phase) only:
  • Cohort 1: TP53 wt and MDM2-amplified sarcoma with advanced/ disease at any line of therapy. If TP53 status is not available during screening, the patient may be included with unknown TP53 status if a tissue sample is submitted for central laboratory assessment. If TP53 status cannot be evaluated, the patient may be included if agreed between the Investigator and Sponsor.
  • Cohort 2: TP53 wt and MDM2- amplified NSCLC, urothelial, gastric, biliary tract (including cholangiocarcinoma, intra- and extrahepatic biliary tree, gall blander and ampulla of vater) or pancreatic solidPDAC tumors who have had at least one previous line of therapy for advanced/metastatic disease. If TP53 status cannot be evaluated the patient may be included if agreed between the Investigator and Sponsor
  • Phase Ia (dose escalation) only:
  • Patient with either measurable or non-.
  • Non-evaluable disease allowed.
  • Phase Ib (expansion phase) only:
  • At least one target lesion that can be accurately measured per v.1.1.
  • Phase Ia:
  • Patient must be willing to undergo blood sampling for PK, pharmacodynamic, biomarker, and PGx analyses.
  • Phase Ib:
  • Patient must be willing to undergo tumor sampling for pharmacodynamic analyses and blood sampling for PK, pharmacodynamics, and biomarker analyses.
  • Willingness to provide a fresh tumor tissue sample obtained after relapse/ progression during or after prior therapy. In case a fresh biopsy cannot be obtained (e.g. inaccessible lesions or patient safety concern), an archived specimen, collected before screening within 12 months of enrollment, may be submitted. If these requirements cannot be met, then the patient may be allowed to enter the study at Sponsor discretion, after agreement between the Investigator and Sponsor.
  • Further inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Previous administration of BI 907828 (brigimadlin) or any other MDM2-p53 or MDMX (MDM4)-p53 antagonist.
  • Known TP53 mutant tumor.
  • Symptomatic from non-brain tumors. Note: Patients with previously treated may participate provided they are stable, without evidence of progression by imaging (using the identical imaging modality for each assessment, either MRI or computed tomography (CT) scan), for at least four weeks prior to the first dose of trial treatment, and any neurologic symptoms have returned to baseline; have no evidence of new or enlarging brain metastases. Patients on must have a stable dose for at least 5 days prior to baseline MRI.
  • Patients with history of bleeding diathesis.
  • Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to start of study treatment, or planned within 12 months after screening (e.g. hip replacement).
  • Any other documented active or suspected or history of malignancy within 3 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix, or other local tumors considered cured by local treatment.
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Drug: BI 907828

  • Experimental
    Dose Expansion

    Drug: BI 907828

Interventions

  • Film-coated tablet

    Also known as: brigimadlin

06

What researchers measure

Primary outcomes

  1. Phase Ia- Maximum tolerated dose (MTD) based on number of patients with dose limiting toxicities (DLTs) during first treatment cycle

    Time frame: Up to 28 days

  2. Phase Ib - Progression-free survival

    Time frame: Up to 24 months

  3. Phase Ia - Number of patients with DLTs during first treatment cycle (21 days, Arm A; 28 days, Arm B)

    Time frame: Up to 28 days

  4. Phase Ib - Number of patients with DLTs during the first treatment cycle

    Time frame: Up to 28 days

Secondary outcomes

  1. Phase Ia - Cmax: Maximum measured concentration of BI 907828 in plasma

    Time frame: Up to 24 months

  2. Phase Ia - AUC0-∞: Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity

    Time frame: Up to 24 months

  3. Phase Ib - Objective response

    Time frame: Up to 24 months

  4. Phase Ib - Overall survival

    Time frame: Up to 24 months

  5. Phase Ib - Number of patients with Grade ≥3 treatment-related adverse events observed during the entire treatment period

    Time frame: Up to 24 months

  6. Phase Ib - Cmax: Maximum measured concentration of BI 907828 in plasma

    Time frame: Up to 24 months

  7. Phase Ib - AUC0-∞: Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity

    Time frame: Up to 24 months

07

Study locations

27 sites
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06511, United States
  • Florida Cancer Specialists-Sarasota-61670
    Sarasota, Florida 34232, United States
  • Norton Cancer Institute, Downtown
    Louisville, Kentucky 40202, United States
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Rigshospitalet, København
    København Ø, 2100, Denmark
  • Helios Klinikum Berlin-Buch
    Berlin, 13125, Germany
  • Universitätsklinikum Köln (AöR)
    Cologne, 50937, Germany
  • Universitätsmedizin Göttingen, Georg-August-Universität
    Göttingen, 37075, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • National Cancer Center Hospital
    Tokyo, Chuo-ku, 104-0045, Japan
  • MED POLONIA SP Z O O, Clinical Trials Department,Poznan
    Poznan, 60-693, Poland
  • Oncology Center-Maria Sklodowska-Curie Institute
    Warsaw, 02-781, Poland
  • Severance Hospital
    Seoul, 03722, South Korea
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Clínico de Santiago
    Santiago de Compostela, 15706, Spain
  • Karolinska Comprehensive Cancer Center
    Stockholm, 171 76, Sweden
08

References and documents

Publications

  • LoRusso P, Yamamoto N, Patel MR, Laurie SA, Bauer TM, Geng J, Davenport T, Teufel M, Li J, Lahmar M, Gounder MM. The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study. Cancer Discov. 2023 Aug 4;13(8):1802-1813. doi: 10.1158/2159-8290.CD-23-0153. PubMed 37269344 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Nov 2025, 88 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 88 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2018
First posted
Feb 28, 2018
StartActual
Jun 20, 2018
Primary completionActual
Nov 13, 2025
CompletionActual
Nov 13, 2025
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03449381
Responsible party
Sponsor
First posted
Feb 28, 2018
Start date
Jun 20, 2018
Primary completion
Nov 13, 2025
Completion
Nov 13, 2025
Last update
Mar 31, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brigimadlin

Start the discussion